Therapeutic opportunities for targeting the ubiquitous cell surface receptor CD47
Year: 2012
Type: review
Abstract: INTRODUCTION: CD47 is a ubiquitously expressed cell surface receptor that serves as a counter-receptor for SIRPα in recognition of self by the innate immune system. Independently, CD47 also functions as an important signaling receptor for regulating cell responses to stress. AREAS COVERED: We review the expression, molecular interactions, and pathophysiological functions of CD47 in the cardiovascular and immune systems. CD47 was first identified as a potential tumor marker, and we examine recent evidence that its dysregulation contributes to cancer progression and evasion of anti-tumor immunity. We further discuss therapeutic strategies for enhancing or inhibiting CD47 signaling and applications of such agents in preclinical models of ischemia and ischemia/reperfusion injuries, organ transplantation, pulmonary hypertension, radioprotection, and cancer. EXPERT OPINION: Ongoing studies are revealing a central role of CD47 for conveying signals from the extracellular microenvironment that limit cell and tissue survival upon exposure to various types of stress. Based on this key function, therapeutics targeting CD47 or its ligands thrombospondin-1 and SIRPα could have broad applications spanning reconstructive surgery, engineering of tissues and biocompatible surfaces, vascular diseases, diabetes, organ transplantation, radiation injuries, inflammatory diseases, and cancer.
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: green
Awards: Roles of CD47 Signaling in Tumor Immunology, Biodegradable Synthetic Vascular Graft, TSP1-CD47 in Promotion of PAH-Associated Vasoconstriction and Vascular Overgrowth, Therapeutic Targeting of Vascular Subphenotypes of Lung Disease, TSP-1 and ROS: CD47 and SIRP-alpha as Mediators of Vascular Dysfunction, G7659836770, Cellular Interactions with Thrombospondin, G832719042
OpenAlex ID: W1990908331